Back to Archived News
Imaging Diagnostic Systems Receives Second Patent for Small Animal Optical Scanner
Wednesday, May 09, 2007
Fort Lauderdale, FL -- Imaging Diagnostic Systems, Inc., (OTCBB: IMDS) a pioneer in laser optical breast imaging systems, has had a new patent issued for its Laser Imager for Laboratory Animals (LILA). The latest LILA patent, US Letters Patent 7,212,848, Optical Computed Tomography Scanner for Small Laboratory Animals, builds on the previous LILA patent, US 7,155,274, of the same title.
The original LILA patent covers the basic computed tomographic fluorescent imaging of small laboratory animals. This patent, issued May 1, 2007, adds the concept of a second laser, typically at a longer wavelength, to provide a geographic reference for the fluorescence image. This application provides both functional and anatomic information, similar to that provided by a more expensive small animal CT/PET scanner. Small animal imaging has the potential to provide higher-quality in vivo information in pharmaceutical research labs and could lead to quicker drug discovery.
This patent is the 12th issued to IMDS with applicability to small animal optical imaging. IMDS previously licensed its unique optical animal imaging technologies on an exclusive basis to Bioscan, Inc., of Washington, D.C. IMDS has received from Bioscan full payment of a $250,000 technology transfer fee and is entitled to future royalty payments as the licensed products are commercialized.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth. Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification. For more information, visit our corporate website: http://www.imds.com.
Back to Archived News
